Zenas BioPharma Reports Q3 Revenue of $10 Million and GAAP EPS Miss
Zenas BioPharma (ZBIO) reported third-quarter financial results that fell short of analyst expectations. The company posted a GAAP earnings per share (EPS) of -$1.65, missing consensus estimates by $0.41. Total revenue for the quarter was recorded at $10 million. Despite the earnings miss, the company maintains a significant liquidity position. As of September 30, 2026, Zenas BioPharma reported having $647.1 million in cash, cash equivalents, and investments to support its ongoing operations and development programs.
Tickers: $ZBIO
Topics: cash position earnings miss revenue report